Skip to main content
SpringerLink
Log in

Leptomeningeal metastases: A review of evaluation and treatment

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Leptomeningeal metastases (LM) is a common problem in neuro-oncology occurring in approximately 5% of all patients with cancer. Notwithstanding frequent focal signs and symptoms in LM, LM is a disease affecting the entire neuraxis and therefore staging and treatment need encompass all cerebrospinal fluid (CSF) compartments. Central nervous system (CNS) staging of LM includes contrast enhanced cranial computerized tomography (CE-CT) or magnetic resonance imaging (MR-Gd), contrast enhanced spine magnetic resonance imaging (MR-S) or computerized tomographic myelography (CT-M) and radionuclide CSF flow study (FS). Treatment of LM involves involved-field radiotherapy of bulky or symptomatic disease sites and intra-CSF drug therapy. The inclusion of concomitant systemic therapy may benefit patients with LM and may obviate the need for intra-CSF chemotherapy. At present, intra CSF drug therapy is confined to three chemotherapeutic agents (i.e. methotrexate, cytosine arabinoside and thio-TEPA) administered by a variety of schedules either by intralumbar or intraventricular drug delivery. Although treatment of LM is palliative with an expected median patient survival of 6 months, it often affords stabilization and protection from further neurologic deterioration in patients with LM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Olson M, Chernik N, Posner J: Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 30: 122–137, 1974

    Google Scholar 

  2. Little J, Dale A, Okazaki H: Meningeal carcinomatosis. Clinical manifestations. Arch Neurol 30: 138–143, 1974

    Google Scholar 

  3. Shapiro W, Posner J, Ushio Y, Chernik N, Young D: Treatment of meningeal neoplasms. Cancer Treat Rep 61: 733–743, 1977

    Google Scholar 

  4. Theodore WH, Gendelman S: Meningeal carcinomatosis. Arch Neurol 38: 696–699, 1981

    Google Scholar 

  5. Wasserstrom W, Glass J, Posner J: Diagnosis and treatment of leptomeningeal metastases from solid tumors experience with 90 patients. Cancer 49: 759–772, 1982

    Google Scholar 

  6. Kaplan J, DeSouza T, Farkash A, Shafran B, Pack D, Rehman F, Fuks J, Portenoy R: Leptomeningeal metastases comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neuro-Oncol 92: 25–229, 1990

    Google Scholar 

  7. Chamberlain M, Corey-Bloom J: Leptomeningeal metastases 111Indium-DTPA CSF flow studies. Neurology 41: 1765– 1769, 1991

    Google Scholar 

  8. Posner J, Chernik N: Intracranial metastases from systemic cancer. Adv Neurol 19: 579–591, 1978

    Google Scholar 

  9. Packer R, Siegel K, Sutton L, Litmann P, Bruce D, Schut L: Leptomeningeal dissemination of primary central nervous system tumors of childhood. Ann Neurol 18: 217–221, 1985

    Google Scholar 

  10. Yung W, Horten B, Shapiro W: Meningeal gliomatosis. A review of 12 cases. Ann Neurol 8: 605–608, 1980

    Google Scholar 

  11. Awad I, Bay J, Rogers L: Leptomeningeal metastasis from supratentorial malignant gliomas. Neurosurgery 19: 247–251, 1986

    Google Scholar 

  12. Civitello L, Packer R, Rorke L, Siegel K, Sutton L, Schut L: Leptomeningeal dissemination of low-grade gliomas in childhood. Neurology 38: 562–566, 1988

    Google Scholar 

  13. Chamberlain M, Dirr L: Involved field radiotherapy and intra-Ommaya methotrexate/ara-C in patients with AIDS-related lymphomatous meningitis. J Clin Oncol 11: 1978–1984, 1993

    Google Scholar 

  14. Rosen S, Aisner J, Makuch R, Matthews M, Ihde D, Whitacre M, Glatstein E, Wiernik P, Lichter A, Bunn Jr P: Carcinomatous leptomeningitis in small cell lung cancer. A clinicopathologic review of the National Cancer Institute experience. A J Med 61: 45–53, 1982

    Google Scholar 

  15. Glass J, Melamed M, Chernik N, Posner J: Malignant cells in cerebrospinal fluid (CSF). The meaning of a positive CSF cytology. Neurology 29: 1369–1375, 1979

    Google Scholar 

  16. Murray J, Greco F, Wolff S, Hainsworth J: Neoplastic meningitis. Marked variations of cerebrospinal fluid composition in the absence of extradural block. Am J Med 75: 289–294, 1983

    Google Scholar 

  17. Schold S, Wasserstrom W, Fleisher M, Schwartz M, Posner J: Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol 85: 97–604, 1980

    Google Scholar 

  18. Ernerudh J, Olsson T, Berlin G, von Schenck H: Cerebrospinal fluid immunoglobulins and 8[IN]2-microglobulin in lymphoproliferative and other neoplastic diseases of the central nervous system. Arch Neurol 44: 915–920, 1987

    Google Scholar 

  19. Klee G, Tallman R, Goellner J, Yanagihara T: Elevation of carcinoembryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosis. Mayo Clin Proc 6: 19–13, 1986

    Google Scholar 

  20. Schipper H, Bardosi A, Jacobi C, Felgenhauer K: Meningeal carcinomatosis origin of local IgG production in the CSF. Neurology 38: 413–416, 1988

    Google Scholar 

  21. Newton H, Fleisher M, Schwartz M, Malkin M: Glucosephosphate isomerase as a CSF marker for leptomeningeal metastasis. Neurology 41: 395–398, 1991

    Google Scholar 

  22. Malkin M, Posner J: Perspectives and commentaries: Cerebrospinal fluid tumor markers for the diagnosis and management of leptomeningeal metastases. Eur J Cancer Clin Oncol 22: 387–392, 1986

    Google Scholar 

  23. Cibas E, Malkin M, Posner J, Melamed M: Detection of DNA abnormalities by flow cytometry in cells from cerebrospinal fluid. Am J Clin Pathol 88: 570–577, 1987

    Google Scholar 

  24. Grossman S, Moynihan T: Neurologic complications of systemic cancer: Neoplastic meningitis. Neurol Clin 9: 843–856, 1991

    Google Scholar 

  25. Recht L: Neurologic complications of systemic cancer: Neurologic complications of systemic lymphoma. Neurol Clin 9: 1001–1015, 1991

    Google Scholar 

  26. Walker R: Neurologic complications of systemic cancer: Neurologic complications of leukemia. Neurol Clin 9: 989–999, 1991

    Google Scholar 

  27. Chamberlain M, Sandy A, Press G: Leptomeningeal metastasis. A comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 40: 435–438, 1990

    Google Scholar 

  28. Jaeckle K, Krol G, Posner J: Evolution of computed tomographic abnormalities in leptomeningeal metastases. Ann Neurol 17: 85–89, 1985

    Google Scholar 

  29. Lee Y, Glass J, Geoffray A, Wallace S: Cranial computed tomographic abnormalities in leptomeningeal metastasis. AJR 143: 1035–1039, 1984

    Google Scholar 

  30. Ascherl Jr G, Hilal S, Brisman R: Computed tomography of disseminated meningeal and ependymal malignant neoplasms. Neurology 31: 567–574, 1981

    Google Scholar 

  31. Sze G, Soletsky S, Bronen R, Krol G: MR imaging of the cranial meninges with emphasis on contrast enhancements and meningeal carcinomatosis. AJNR 10: 965–975, 1989

    Google Scholar 

  32. Kim K, Ho S, Weinberg P, Lee C: Spinal leptomeningeal infiltration by systemic cancer myelographic features. AJR 139: 361–365, 1982

    Google Scholar 

  33. Krol G, Sze G, Malkin M, Walker R: MR of cranial and spinal meningeal carcinomatosis comparison with CT and myelography. AJNR 9: 709–714, 1988

    Google Scholar 

  34. Kramer E, Rafto S, Packer R, Zimmerman R: Comparison of myelography with CT follow-up versus gadolinium MRI for subarachnoid metastatic disease in children. Neurology 41: 46–50, 1991

    Google Scholar 

  35. Sze G, Abramson A, Krol G, Liu D, Amster J, Zimmerman R, Deck M: Gadolinium-DTPA in the evaluation of intradural extramedullary spinal disease. AJNR 9: 153–163, 1988

    Google Scholar 

  36. Lim V, Sobel D, Zyroff J: Spinal cord pial metastases MR imaging with gadopentetate dimeglumine. AJNR 11: 975–982, 1990

    Google Scholar 

  37. Pedersen A, Paulsen O, Gyldensted C: Metrizamide myelography in patients with small cell carcinoma of the lung suspected of meningeal carcinomatosis. J Neurol Oncol 3: 85–89, 1985

    Google Scholar 

  38. Wiener M, Boyko O, Friedman H, Hockenberger B, Oakes W: False-positive spinal MR findings for subarachnoid spread of primary CNS tumor in postoperative pediatric patients. AJNR 11: 1100–1103, 1990

    Google Scholar 

  39. Rippe D, Boyko O, Friedman H et al.: Gd-DTPA-enhanced MR imaging of leptomeningeal spread of primary CNS tumor in children. AJNR 11: 329–332, 1990

    Google Scholar 

  40. Chamberlain MC: Comparative spine imaging in leptomeningeal metastases. J Neuro-Oncol 23: 233–238, 1995

    Google Scholar 

  41. Larson S, Johnston G, Ommaya A, Jones E, Di Chiro G: The radionuclide ventriculogram. JAMA 224: 853–857, 1973

    Google Scholar 

  42. Di Chiro G, Hammock M, Bleyer A: Spinal descent of cerebrospinal fluid in man. Neurology 26: 1–8, 1976

    Google Scholar 

  43. Lyons M, Meyer F: Subject review: Cerebrospinal fluid physiology and the management of increased intracranial pressure. Mayo Clin Proc 65: 684–707, 1990

    Google Scholar 

  44. Chamberlain M: Pediatric leptomeningeal metastasis 111Indium-DTPA CSF flow studies. J Child Neurol 9: 150–154, 1994

    Google Scholar 

  45. Chamberlain M: Spinal 111Indium-DTPA CSF flow studies in leptomeningeal metastasis. J Neuro-Oncol 25: 135–141, 1995

    Google Scholar 

  46. Kokkoris C: Leptomeningeal carcinomatosis: How does cancer reach the pia-arachnoid? Cancer 51: 154–160, 1983

    Google Scholar 

  47. Gonzalez-Vitale J, Garcia-Bunuel R: Meningeal carcinomatosis. Cancer 37: 2906–2911, 1976

    Google Scholar 

  48. Blasberg R, Patlak C, Fenstermacher J: Intrathecal chemotherapy brain tissue profiles after ventriculo-cisternal perfusion. Pharm Exp Ther 195: 73–83, 1975

    Google Scholar 

  49. Slevin M, Piall E, Aherne G, Harvey V, Johnston A, Lister T: Effect of dose and schedule on pharmacokinetics of highdose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1: 546–551, 1983

    Google Scholar 

  50. Lopez J, Nassif E, Vannicola P, Kirkorian J, Agarwal R: Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neuro-Oncol 3: 119–124, 1985

    Google Scholar 

  51. Ackland S, Schilsky R: Review article. High-dose methotrexate: A critical reappraisal. J Clin Oncol 5: 2017–2031, 1987

    Google Scholar 

  52. Balis F, Poplack D: Central nervous system pharmacology of antileukemic drugs. Am J Pediat Hemat/Oncol 11: 74–86, 1989

    Google Scholar 

  53. Collins J: Pharmacokinetics of intraventricular administration. J Neuro-Oncol 1: 283–291, 1983

    Google Scholar 

  54. Shapiro W, Young D, Mehta B: Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293: 161–166, 1975

    Google Scholar 

  55. Bleyer W: Current status of intrathecal chemotherapy for human meningeal neoplasms. NCI Monogr 46: 171–178, 1977

    Google Scholar 

  56. Gutin P, Weiss H, Wiernik P, Walker M: Intrathecal N, N′, N″-triethylenethiophosphoramide [thio-TEPA (NSC 6369)] in the treatment of malignant meningeal disease; Phase I-II study. Cancer 38: 1471–1475, 1976

    Google Scholar 

  57. Gutin P, Levi J, Wiernik P, Walker M: Treatment of malignant meningeal disease with intrathecal thio-TEPA. A phase II study. Cancer Treat Rep 61: 885–887, 1977

    Google Scholar 

  58. Fulton D, Levin V, Gutin P, Edwards M, Seager M, Stewart J, Wilson C: Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol 8: 285–291, 1982

    Google Scholar 

  59. Strong J, Collins J, Lester C, Poplack D: Pharmacokinetics of intraventricular and intravenous N, N′, N″-triethylenethiophosphoramide (Thiotepa) in Rhesus monkeys and humans. Cancer Res 46: 6101–6104, 1986

    Google Scholar 

  60. Jaeckle K, Lukes S, Krown S, Krim M, Oettgen H, Nielsen S, Posner J: Phase I study of intraventricularly administered human interferon in patients with leptomeningeal tumor. Ann Neurol 14: 138–139, 1983

    Google Scholar 

  61. Blacklock J, Grimm E, Loudon W, Moser R, Rutledge M, Katz R: CNS tumors: 362 intraventricular interleukin-2 in the treatment of leptomeningeal melanomatosis, phase I clinical trial and kinetic study. Proc ASCO 8: 93, 1989

    Google Scholar 

  62. Lashford L, Davies G, Richardson R, Bourne S, Bullimore J, Eckert H, Kemshead J, Coakham H: A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer 61: 857–868, 1988

    Google Scholar 

  63. Berg S, Ballis F, Zimm S, Murphy R, Holcenberg J, Sato J, Reaman G, Steinherz P, Gillespie A, Doherty K, Poplack D: Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 10: 143–148, 1992

    Google Scholar 

  64. Arndt C, Colvin O, Balis F, Lester C, Johnson G, Poplack D: Intrathecal administration of 4-hydroperoxycyclophosphamide in Rhesus monkeys. Cancer Res 47: 5932–5934, 1987

    Google Scholar 

  65. Chamberlain M, Khatibi S, Kim J, Howell S, Chatelut E, Kim S: Leptomeningeal metastasis with intraventricular Depo/ara-C: a phase I study. Arch Neurol 50: 261–264, 1993

    Google Scholar 

  66. Kim S, Chatelut E, Kim J, Howell S, Cates C, Kormanik P, Chamberlain M: Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 11: 2186–2193, 1993

    Google Scholar 

  67. Giannone L, Greco F, Hainsworth J: Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 4: 68–73, 1986

    Google Scholar 

  68. Hitchens R, Bell D, Woods R, Levi J: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5: 1655–1662, 1987

    Google Scholar 

  69. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS: Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 11: 561–569, 1993

    Google Scholar 

  70. Chamberlain MC, Kormanik PA: Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neuro-surgery 87: 694–699, 1997

    Google Scholar 

  71. Lishner M, Perrin R, Feld R, Messner H, Tuffnell P, Path FRC, Elhakim T, Matlow A, Curtis J: Complications associated with Ommaya reservoirs in patients with cancer. Arch Intern Med 150: 173–176, 1990

    Google Scholar 

  72. Chamberlain MC, Kormanik P: Leptomeningeal metastases due to melanoma: combined modality therapy. Intern J Oncol 9: 505–510, 1996

    Google Scholar 

  73. Chamberlain MC, Kormanik PA: Cardinomatous meningitis secondary to breast cancer: Combined modality therapy. J Neuro-Oncol 35: 55–64, 1997

    Google Scholar 

  74. Glantz M, Hall WA, Cole BF et al.: Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow studies. Cancer 75: 2919–2931, 1995

    Google Scholar 

  75. Grant R, Naylor B, Greeberg HS, Junck L: Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 51: 457–461, 1994

    Google Scholar 

  76. Balm M, Hammack J: Leptomeningeal carcinomatosis. Arch Neurol 53: 626–632, 1996

    Google Scholar 

  77. Chamberlain MC, Kormanik P: Prognostic significance of 111Indium-DTPA CSF flow studies. Neurology 46(6): 1674–1677, 1996

    Google Scholar 

  78. Chamberlain MC, Kormanik PA: Prognostic significance of co-existent bulky metastatic CNS disease in patients with leptomeningeal metastases. Arch Neurol, in press

  79. Freilich RJ, Krol G, DeAngelis LM: Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 38: 51–57, 1995

    Google Scholar 

  80. Siegal T, Lassos A, Pfeffer MR: Leptomeningeal metastases: Analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 44: 1463–1469, 1994

    Google Scholar 

  81. Boogerd W, Hart AAM, Van der Sande JJ, Engelsman E: Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67: 1685–1695, 1991

    Google Scholar 

  82. Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, Beuzeboc P, Dorval T, Pouillart P: Meningeal carcinomatosis in patients with breast carcinoma. Cancer 77(7): 1315–1323, 1996

    Google Scholar 

  83. Dedrick R, Zaharko D, Bender R, Bleyer W, Lutz R: Pharmacokinetic considerations on resistance to anticancer drugs. Cancer Chemother Rep 59: 795–804, 1975

    Google Scholar 

  84. Grossman S, Trump D, Chen D, Thompson G, Camargo E: Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. Am J Med 73: 641–647, 1982

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Southern California Kaiser Permanente, t[Baldwin Park, California, USA

    Marc C. Chamberlain

Authors
  1. Marc C. Chamberlain
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chamberlain, M.C. Leptomeningeal metastases: A review of evaluation and treatment. J Neurooncol 37, 271–284 (1998). https://doi.org/10.1023/A:1005976926058

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005976926058

Search

Navigation